A number of different approaches have been developed to generate vaccines against tumors. Many of these approaches are based on genetically engineered tumor cells that are immunogenic, and thereby efficiently stimulate the generation of tumor-specific effector cells. Some of the engineered tumor cells secrete cytokines such as interleukin-2 (IL-2) that bypass the need for helper cells. The inoculation of cytokinesecreting tumor cells into syngeneic mice induces tumor regression, which further leads to long-term protective immunity against a second challenge of the parental tumor cells. [1] [2] [3] [4] The latter immunity is mostly mediated by tumor-specific and major histocompatibility complexrestricted CD8 ϩ cytotoxic T lymphocytes. 1, 2 However, cancer immunotherapy employing these engineered tumor cells as vaccines is usually unsuccessful in inducing regression of pre-established tumors when the vaccine is administered in sites anatomically distant to the tumor locations. 5 It is clear that antigen (Ag) recognition by itself is not sufficient for activation of T-cell effector functions. Additional signals such as the costimulatory molecule B7-1 are also critical for the generation of T-cell mediated immunity. Ag recognition in the absence of these second signals can lead to tolerance or anergy. 6 As such, costimulation plays an important role in antitumoral immunity. 7, 8 The cotransfection of engineered tumor cells with genes coding for cytokines and the costimulatory molecule B7-1 significantly increased their efficiency in stimulating antitumoral immune responses. 9, 10 Although such modified tumor cells are more effective immunogens when administered before challenge with wild-type tumors, their effectiveness in mediating the rejection of large well-established tumors has not been established.
The recombinant adenovirus (AdV) has facilitated gene transfer into a variety of cell types, both benign and malignant. 11, 12 Deletion of the early region 1 (E1) genes renders the AdV replication-deficient. Combining E1 deletion with another deletion of the nonessential E3 region results in AdV vectors with a capacity to carry up to 8 kb of inserted genes. 13 Furthermore, the ability to produce large quantities of this virus in purified form with relative ease makes this system attractive for cancer gene therapy. Recently, cancer gene therapy using recombinant adenoviral vectors expressing cytokines was reported to have been successful in animal models; 14 -16 however, this only dealt with inhibition of tumor growth in the early stages of neoplasia. Therefore, with regard to therapeutic approaches using either cancer vaccines or cancer gene therapy, the major challenge that remains is how to combat well-established tumors.
We have shown previously that the engineered tumor cell V K C K /RM4-TNF-␣ secretes the fusion protein RM4/TNF-␣, which contains the cytokine moiety tumor necrosis factor-␣ (TNF-␣). The local secretion of RM4/ TNF-␣ by engineered tumor cells significantly reduced the tumorigenicity of the wild-type tumor in vivo and further induced protective immunity against it. 17 However, vaccination of V K C K /RM4-TNF-␣ cells was unable to inhibit established tumor growth in vivo. In addition, we also previously constructed a recombinant adenoviral vector, pLpA-M4-TNF-␣. The infection of V K C K cells in vitro with pLpA-M4-TNF-␣ resulted in secretion of the fusion protein RM4/TNF-␣ in the culture supernatant at 35 ng/mL/10 6 cells by infected V K C K cells. Intratumoral (i.t.) vaccination with pLpA-M4-TNF-␣ induced regression of V K C K tumors in the early stages, 18 but this approach was unsuccessful for well-established tumors. 19 In the current study, the engineered tumor cells, V K C K / RM4-TNF-␣, were further transfected with the costimulatory molecule B7-1 gene to enhance their immunogenicity. However, over and above this, the main thrust of the present study was to attempt to combat well-established tumors. To this end, we investigated the utility of combinational immunotherapy with (a) AdV-mediated TNF-␣ gene transfer and (b) cancer vaccine using engineered tumor cells secreting TNF-␣ and expressing B7-1.
MATERIALS AND METHODS

Antibodies (Abs), tumor cell lines, recombinant AdV, and animals
The rat monoclonal Abs GK1.5 (anti-CD4) and 3.155 (anti-CD8) were purified from the ascites of respective hybridoma cell lines obtained from the American Type Culture Collection (Manassas, Va). Rat anti-mouse B7-1 Ab was obtained from PharMingen (San Diego, Calif). Fluorescein isothiocyanate (FITC)-conjugated goat anti-rat immunoglobulin G (IgG) Ab was obtained from Bio/Can Scientific (Missassauga, Ontario, Canada). The V K C K cell line expressing the cytoplasmic chimeric light chain (V K C K ) of ccM4 Ab was derived from a BALB/c mouse myeloma cell line, SP2/0Ag14, by transfection with a chimeric light chain expression vector, mpSV2gpt-EP-V K C K . 20 The V K C K /RM4-TNF-␣ cell line, which secretes the recombinant fusion protein RM4/TNF-␣, was derived from the V K C K cell line by transfection with an expression vector, mpSV2neo-EP-M4-TNF-␣, expressing the heavy chain fused gene fragment M4-TNF-␣. 21 The fusion protein containing the heavy chain (M4-TNF-␣) and the light chain (V K C K ) was secreted from V K C K /RM4-TNF-␣ cells when the heavy and light chains were associated within the cells. The fusion protein RM4/TNF-␣ was only used as a source of TNF-␣ in this study. The V K C K /RM4-TNF-␣ cell line (shortened to V K C K -TNF-␣) was maintained in Dulbecco's modified Eagle's medium (DMEM) plus 10% fetal calf sera (FCS) with 0.8 g/mL mycophenolic acid and 0.5 mg/mL G418. MCA-26 is a colon adenocarcinoma cell line of BALB/c mouse origin and was maintained in DMEM medium plus 10% FCS. The recombinant AdV pLpA-M4-TNF-␣ (AdV-TNF-␣) is an E1-deleted, replication-deficient AdV expressing the fusion protein RM4-TNF-␣. 18 The AdV pLpA (AdV-pLpA) lacking expression of any transgene was used as a control in this study. Female BALB/c mice (4 -6 weeks of age) were obtained from a colony bred at the Animal Resource Center, University of Saskatchewan. Female athymic nude mice (4 -6 weeks of age) were obtained from Charles River Laboratories (St. Constant, Quebec, Canada). All mice were maintained in our animal facility at the Saskatoon Cancer Center.
Transfection of tumor cells with the expression vector pcDNA-B7-1 in vitro A 1-kb cDNA fragment coding for the full open reading frame of mouse B7-1 gene was cloned by reverse transcription polymerase chain reaction from a cDNA library of lipopolysaccharide-stimulated mouse spleen B cells using the TaqI polymerase. Two polymerase chain reaction primers were used, namely, the sense primer (5Ј-ctcca ttggc tctag attcc-3Ј) and the antisense primer (5Ј-cctca tgagc cacat aatac-3Ј). The cloned cDNA fragment was ligated into the pCR2.1 vector (Invitrogen, Carlsbad, Calif) to form pCR2.1-B7-1. The B7-1 sequence was verified by the dideoxy nucleotide sequencing method. The cDNA fragment of B7-1 ((HindIII/XbaI) from the pCR2.1-B7-1 vector was further ligated into the pcDNA3.1/Hygro vector (Invitrogen) to form pcDNA3.1/Hygro-B7-1 (pcDNA-B7-1). Twenty million V K C K -TNF-␣ cells were resuspended in 0.7 mL of phosphate-buffered saline (PBS) and mixed with 0.3 mL of PBS containing 10 g of pcDNA-B7-1 DNA. Tumor cells were transfected with pcDNA-B7-1 using a Bio-Rad gene pulser (Bio-Rad, Richmond, Calif) with parameters of 250 V and 125 FD capacitance. The transfected cells were selected for growth in complete medium plus 0.8 g/mL mycophenolic acid, 0.5 mg/mL G418, and 3 mg/mL hygromycin. The selected clone V K C K -TNF-␣/B7-1 was used for analysis of the surface expression of B7-1 by flow cytometry in vitro and for animal studies in vivo.
B7-1 expression of transfected tumor cells
To examine the B7-1 expression of V K C K -TNF-␣/B7-1 tumor cells, a quantitative analysis of B7-1 on the tumor cell surface was performed by using a fluorescence-activated cell sorter (FACS) (Epics XL; Coulter, Burlington, Ontario, Canada). Briefly, various tumor cell lines were first incubated with rat anti-B7-1 Ab (2 g/mL) on ice for 1 hour. After three washes with PBS, cells were further incubated with FITC-conjugated anti-rat IgG Ab (5 g/mL) for an additional 1 hour on ice. After another three washes with PBS, cells were analyzed for the expression of B7-1 by flow cytometry.
Animal studies
To study the tumorigenicity of V K C K -TNF-␣/B7-1 cells, naive BALB/c mice (eight per group) were subcutaneously (s.c.) inoculated in their right thighs with 0.5 ϫ 10 6 V K C K -TNF-␣/ B7-1 and V K C K tumor cells, respectively. In another group of mice bearing V K C K tumors of 10 days duration (ϳ5 mm in diameter) in their left thighs, 0.5 ϫ 10 6 V K C K -TNF-␣/B7-1 tumor cells were further s.c. inoculated into their right thighs. Mice were then monitored for tumor progression or regression. Animals were sacrificed 2 weeks after tumor inoculation. Tumors were carefully removed and weighed. Tumor growth was confirmed by histologic analysis.
To study the mechanisms involved in the reduced tumorigenicity of V K C K -TNF-␣/B7-1 cells, we performed a second and a third animal study. In the second study, 0.5 ϫ 10 6 V K C K -TNF-␣/B7-1 and V K C K cells were s.c. injected into the right thighs of nude mice (six per group). In the third animal study, 0.5 ϫ 10 6 V K C K -TNF-␣/B7-1 cells were s.c. injected into the right thighs of CD4 ϩ or CD8 ϩ T-cell subset-depleted naive mice. Experiments relating to the depletion of the T-cell subset in vivo were performed as described previously. 2 Briefly, naive BALB/c mice and mice bearing V K C K tumors (eight per group) were injected twice intravenously with anti-CD4 and anti-CD8 Abs at 1.0 mg per mouse 1 day before and 5 days after the inoculation of 0.5 ϫ 10 6 V K C K -TNF-␣/B7-1 tumor cells, respectively. Depletion of T-cell subsets was monitored by flow cytometry, which showed Ͼ90% specific depletion in splenocytes. As a control, one group of mice was injected with the same amount of normal rat IgG. Mice were sacrificed 2 weeks after tumor inoculation. Tumors were removed and examined as described above.
To examine the protective immunity conferred by tumor inoculation, we performed a fourth animal study. In this study, 0.5 ϫ 10 6 V K C K or MCA-26 tumor cells were inoculated into the right thighs of immunized mice (eight mice per group) that demonstrated tumor regression 2 weeks after the initial inoculation of a V K C K -TNF-␣/B7-1 tumor in their left thighs. In another experiment, V K C K tumor cells at different dosages (0.5 ϫ 10 6 , 3 ϫ 10 6 , 5 ϫ 10 6 , and 7 ϫ 10 6 cells) were inoculated into the right thigh of each immunized mouse. Mice were sacrificed 2 weeks after the tumor inoculation. Tumors were processed as described above.
To study the mechanisms involved in the protective immunity, a fifth animal study was performed. In this study, 0.5 ϫ 10 6 V K C K tumor cells were s.c. injected into the right thighs of immunized mice (eight mice per group) that were further depleted with different T-cell subsets. Mice were monitored for tumor progression or regression and sacrificed 2 weeks after tumor inoculation. Tumors were processed as described above.
To examine whether vaccination of V K C K -TNF-␣/B7-1 tumor cells is able to inhibit the pre-established V K C K tumor growth, a sixth animal study was conducted. In this study, 0.5 ϫ 10 6 V K C K tumor cells were s.c. inoculated into the right thighs of mice. At different timepoints (0, 3, 7, and 10 days) after tumor inoculation, mice were vaccinated by i.p. injection of 2 ϫ 10 6 V K C K -TNF-␣/B7-1 cells. The vaccination of V K C K -TNF-␣/B7-1 was repeated once a week. At 1 week after the third vaccination, the mice in each group were sacrificed. Tumors were processed as described above.
To examine whether combinational immunotherapy with V K C K -TNF-␣/B7-1 vaccine and AdV-mediated TNF-␣ gene transfer is able to inhibit well-established V K C K tumor growth, we carried out a seventh animal study. In this study, 0.5 ϫ 10 6 V K C K cells were s.c. injected into the right thighs of mice. At 5 days after tumor inoculation, each mouse was vaccinated by i.p. injection of 2 ϫ 10 6 V K C K -TNF-␣/B7-1 cells. At 10 -12 days after the initial V K C K inoculation, V K C K tumors grew to ϳ5 mm in diameter. Each mouse was again vaccinated by i.p. injection of 2 ϫ 10 6 V K C K -TNF-␣/B7-1 cells, and each tumor was also injected i.t. with 1 ϫ 10 9 plaque-forming units (PFU) of either AdV-TNF-␣ or AdV-pLpA. The vaccination was repeated once a week and the injection of AdV-TNF-␣ or AdV-pLpA was repeated once every 3 days after the initial injection. The V K C K tumor growth was monitored for another 2 weeks. Tumors were processed as described above. In this experiment, the V K C K -TNF-␣/B7-1 vaccination alone and the i.t. injection of AdV-TNF-␣ alone were used as the controls.
All of the animal studies were performed twice independently. The Student's t test and the nonparametric MannWhitney U test were used to examine the statistical significance in some of these animal studies. 18 Quantitation of cytokine secretion At 1 week after inoculation of 0.5 ϫ 10 6 V K C K and V K C K -TNF-␣/B7-1 tumor cells into mouse footpads, regional lymph nodes were removed for harvesting lymphocytes. These lymphocytes were cocultured with irradiated V K C K cells (6000 rad) at 2:1 (0.5 ϫ 10 6 lymphocytes and 0.25 ϫ 10 6 irradiated V K C K cells per well in a 96-well plate). Coculture was done in quadruplicate, and their supernatants were harvested and pooled at 24 and 96 hours for interferon-␥ (IFN-␥) and IL-4 quantitation, respectively. Quantitation of secreted cytokines was done in an enzyme-linked immunosorbent assay (ELISA) by using the respective cytokine kits for IFN-␥ and IL-4 (Endogen, Woburn, Mass), respectively. The results were normalized to the known standard curves.
T-cell cytotoxicity in vitro and biodistribution in vivo
For the T-cell cytotoxicity assay, mouse spleens were removed from the immunized mice that experienced V K C K -TNF-␣/B7-1 tumor regression and from mice bearing V K C K tumors for preparation of single-cell suspensions by pressing against fine nylon mesh; spleens were then washed with PBS. Red cells were lysed by using 0.84% ammonium chloride. Spleen lymphocytes (5 ϫ 10 6 ) were cocultured with ␥-irradiated (6000 rad) V K C K cells (1 ϫ 10 5 ) in 2 mL of DMEM plus 10% FCS in each well of a 24-well plate (Costar, Cambridge, Mass), respectively. T cells were harvested after 5 days. These T cells were used as effector cells in the chromium release assay. Target cells included V K C K and MCA-26 tumor cells that were radio-labeled with [ 51 Cr]chromate. Radiolabeled target cells were prepared by culture for 1 hour in the presence of 50 L of sodium [ 51 Cr]chromate (36 mCi/mL; Amersham, Oakville, Ontario, Canada) and were washed twice with DMEM. Ten thousand labeled target cells per well were mixed with effector cells at various effector to target cell ratios in triplicate and were incubated for 6 hours. The percentage of specific lysis was calculated as follows: 100 ϫ ([experimental cpm Ϫ spontaneous cpm]/[maximal cpm Ϫ spontaneous cpm]). The maximal cpm were released by adding 1% Triton X-100 to wells in experiments.
In the T-cell biodistribution study, spleen lymphocytes (5 ϫ 10 6 ) of the immunized mice that experienced V K C K -TNF-␣/ B7-1 tumor regression were cocultured with irradiated (6000 rad) V K C K cells (1 ϫ 10 5 ) as described above. T cells were harvested after 5 days. These T cells were then labeled with [ 51 Cr]chromate as described above. After washing twice with PBS, ten million labeled T cells were injected into the tail veins of mice bearing V K C K tumors measuring ϳ5 mm in diameter in their right and left thighs. A day before the tail vein injection of labeled T cells, mice bearing two V K C K tumors were injected i.t. with 1 ϫ 10 9 PFU of AdV-TNF-␣ and AdV-pLpA into their right and left thighs, respectively. The mice were sacrificed at 2 and 24 hours after the tail vein injection of labeled T cells. Each tumor and various other organs were removed and weighed. The radioactivity of each tumor or organ was counted in a gamma counter. The biodistribution of labeled T cells was expressed as the localization index (cpm per gram of tissue).
RESULTS
B7-1 expression
The V K C K -TNF-␣ cell line was transfected with the pcDNA-B7-1 vector to increase its immunogenicity. The B7-1 expression of V K C K -TNF-␣/B7-1 was examined by FACS analysis. As shown in Figure 1 , V K C K -TNF-␣/ B7-1 cells displayed significant amounts of cell surface B7-1 expression, whereas the original V K C K -TNF-␣ showed a very low expression of B7-1 molecule. The TNF-␣ in the form of fusion protein secreted by V K C K -TNF-␣/B7-1 cells into the culture supernatant was estimated to be 40 ng/mL/10 6 cells, which is the same amount secreted by V K C K -TNF-␣ cells. 17 
Reduced tumorigenicity
The in vitro growth rate of V K C K -TNF-␣/B7-1 tumor cells was similar to that of their parental V K C K tumor cells, because their doubling times were 12.4 and 11.8 hours in tissue culture, respectively. To study their tumorigenicity, V K C K -TNF-␣/B7-1 tumor cells were injected s.c. into syngeneic BALB/c mice. As shown in Table 1 , V K C K tumors grew aggressively, with a tumor incidence of 100%. However, the V K C K -TNF-␣/B7-1 cells totally lost their tumorigenicity in syngeneic BALB/c mice.
It is possible that immunization in the pre-established tumor setting failed because of the immune suppression in tumor-bearing mice. To this end, mice with preestablished V K C K tumors on their right thighs were inoculated in their left thighs with V K C K -TNF-␣/B7-1 cells. As shown in Table 1 , the V K C K -TNF-␣/B7-1 transfectant was readily rejected on the contralateral thighs. Thus, tumor-bearing mice could still reject a tumor in a B7-dependent fashion, indicating that immunological tolerance to tumor Ags had not been induced. In addition, rejection of V K C K -TNF-␣/B7-1 tumor did not affect the growth rate of the initial V K C K implants (data not shown), which is consistent with the observation that vaccines with engineered tumor cells might not be sufficient to induce the rejection of large doses or well-established tumors as described below.
Immune mechanisms of tumor growth versus regression
To study the immune mechanisms in the rejection of the V K C K -TNF-␣/B7-1 tumor, V K C K -TNF-␣/B7-1 tumor cells were inoculated into nude mice. Our data showed that V K C K -TNF-␣/B7-1 tumors, which were rejected by immunocompetent mice, grew as aggressively as V K C K tumor cells in all six T-cell-deficient nude mice, indicating that the tumor rejection is mediated by T cells. To further examine which T-cell subset is responsible for the tumor rejection, different T-cell subsets were depleted in naive mice before challenge with the V K C K -TNF-␣/B7-1 cells. As shown in experiment 1 of Table 2 
*Naive mice were inoculated s.c. in their right thighs with 0.5 ϫ 10 6 V K C K , V K C K -TNF-␣, and V K C K -TNF-␣/B7-1 tumor cells, respectively. At 2 weeks after tumor inoculation, tumors were removed and confirmed by histologic analysis.
†Mice bearing V K C K tumors in their left thights were also inoculated s.c. in their right thighs with 0.5 ϫ 10 6 V K C K -TNF-␣/ B7-1 tumor cells. Tumor growth or regression was monitored for 2 weeks after tumor inoculation. The initial V K C K implants in these inoculated mice were also monitored and compared with the V K C K implants in naive mice as controls.
The phenotypes of V K C K -TNF-␣/B7-1-reactive T cells were further evaluated by examining the cytokines they secreted in an ELISA. As shown in Figure 2 , in response to irradiated V K C K cells, T lymphocytes from regional lymph nodes of mice with V K C K -TNF-␣/B7-1 tumor regression secreted high levels of IFN-␥. Lymphocytes from naive or V K C K tumor-bearing mice secreted little or no IFN-␥. In contrast, T lymphocytes from regional lymph nodes of mice with V K C K tumor growth secreted a high level of IL-4 in response to irradiated V K C K cells, whereas a very low level of IL-4 was seen in T lymphocytes derived from regional lymph nodes of naive mice and mice with V K C K -TNF-␣/B7-1 tumor regression. These patterns are consistent with a T helper type 1 (Th1)-dominant response in resistant mice with tumor regression and with a Th2-dominant responses in susceptible mice with tumor growth.
Protective immunity against the parental V K C K tumor To examine whether the reduction in tumorigenicity correlated with the induction of protective immunity against the parental V K C K tumor, eight mice that demonstrated regression of the V K C K -TNF-␣/B7-1 tumor in their left thighs (Table 1) were immediately rechallenged in a similar fashion with parental V K C K or MCR-26 tumor cells in their right thighs 2 weeks after the initial V K C K -TNF-␣/B7-1 inoculation. As shown in experiment 1 (Table 3) , no V K C K tumor growth was found in resistant mice immunized with V K C K -TNF-␣/ B7-1, whereas the incidence of MCR-26 tumor growth was 100%. These results illustrate that mice inoculated with V K C K -TNF-␣/B7-1 tumor cells produced a protective immune response specifically against the parental V K C K tumor, but not against the irrelevant MCR-26 tumor. However, the protective immunity against the parental V K C K tumor cells is dose-dependent. As shown in experiment 2 (Table 3) , tumor growth was found in only one of eight immunized mice after rechallenge with 3 ϫ 10 6 V K C K cells (group B), whereas most of the immunized mice still grew V K C K tumors when challenged with Ն5 ϫ 10 6 V K C K cells (groups C and D). This indicates that the protection is limited to a maximal rechallenge dose of 3 ϫ 10 6 V K C K tumor cells. In contrast, mice immunized with irradiated V K C K cells did not show any protective immunity.
To examine the immune mechanisms involved in this protective immunity, we performed a cytotoxicity assay. Splenocytes from immunized mice were cocultured with irradiated V K C K cells. After 5 days in culture, T lymphocytes were harvested and used as effector cells in a chromium release assay. As shown in Figure 3 , T lymphocytes derived from immunized mice displayed significant cytotoxicity to V K C K cells (87% specific killing at an effector to target cell ratio of 100) but not to irrelevant MCA-26 tumor cells, whereas lymphocytes derived from mice inoculated with irradiated V K C K cells show very low V K C K killing activity (15%). The lymphocytes derived from naive mice did not showed any V K C K killing activity (data not shown). To further confirm that T lymphocytes mediated the protective immunity, V K C K ϩ and CD8 ϩ T-cell-depleted naive mice, respectively. The naive mice that were treated with 1 mg of rat IgG were used as a control (eight mice per group).
†In experiment 2, aliquots of 0.5 ϫ 10 6 V K C K tumor cells were injected s.c. into CD4 ϩ and CD8 ϩ T-cell-depleted mice that previously experienced V K C K -TNF-␣/B7-1 tumor regression and into naive mice as a control.
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tumor cells were inoculated into T-cell subset-depleted immunized mice. As shown experiment 2 ( Table 2) , all eight immunized mice depleted with CD8 ϩ T cells showed significant tumor growth, whereas immunized mice and CD4 ϩ T-cell-depleted immunized mice showed no V K C K tumor growth. These results indicate that CD4 ϩ T cells were required only for the induction of CD8
ϩ -dependent T-cell immunity in the induction phase, but were unnecessary in the effector phase. The antitumoral immunity in the effector phase is primarily mediated by CD8 ϩ T cells.
Inhibition of pre-established parental tumor growth
To examine whether vaccination of V K C K -TNF-␣/B7-1 tumor cells could inhibit the established V K C K tumor growth, mice were inoculated with 0.5 ϫ 10 6 V K C K cells. At different timepoints after tumor inoculation, mice were vaccinated by intraperitoneal injection of 2 ϫ 10 6 V K C K -TNF-␣/B7-1 cells. The vaccination was repeated once a week. As shown in Table 4 , vaccination of V K C K -TNF-␣/B7-1 tumor cells significantly inhibited the 0-and 3-day V K C K tumor growth, whereas the vaccination of V K C K -TNF-␣ cells was unable to inhibit 0-day tumors. However, tumor vaccination with V K C K -TNF-␣/B7-1 had no effect on the growth of 7-and 10-day V K C K tumors. These results indicate that vaccination of V K C K -TNF-␣/B7-1 tumor cells expressing both the B7-1 molecule and the TNF-␣ was able to induce stronger immune responses against pre-established V K C K tumor growth than that of V K C K -TNF-␣ tumor cells, but complete tumor suppression was only seen in the very early stages of the established tumor (3 days). In clinical practice, because most cancer patients have an existing tumor burden, preclinical animal models should examine the question of therapeutic efficacy in the context of established tumors. To this end, a mouse tumor model bearing 10-day established tumors was selected for investigation; these tumors are ϳ5 mm in diameter and have a well-developed vasculature (Fig 4A) . Infection of V K C K cells with pLpA-M4-TNF-␣ resulted in the secretion of TNF-␣ from infected V K C K tumor cells in vitro and in the inhibition of V K C K tumor growth in vivo. 18 To enhance therapeutic efficacy, combinational immunotherapy with gene-modified V K C K -TNF-␣/B7-1 tumor vaccine and AdV-mediated TNF-␣ gene transfer was conducted. At 1 day after i.t. injection of AdV-TNF-␣, tumor necrosis with predominant infiltration of monocytes as well as vascular thrombosis and congestion were seen in the tumors (Fig 4, B and C) . As shown in Table  5 , the treatment of well-established V K C K tumors with AdV-TNF-␣ significantly inhibited tumor growth, resulting in a mean tumor weight of 0.69 g compared with 1.60 g for the control group (P Ͻ .01). V K C K -TNF-␣/ B7-1 vaccination alone (Table 5 ) and its combination with the control AdV-pLpA did not affect tumor growth (data not shown). Although i.t. injection of AdV-TNF-␣ resulted in significant tumor inhibition, it was unable to cure any mice bearing well-established tumors. In contrast, combinational therapy with V K C K -TNF-␣/B7-1 vaccine and i.t. injection of AdV-TNF-␣ significantly inhibited tumor growth, resulting in a mean tumor weight of 0.38 g compared with 0.69 g and 1.60 g for mice treated with an i.t. injection of AdV-TNF-␣ alone and the control mice (P Ͻ .01), respectively. Furthermore, the combinational therapy completely eradicated established tumors in three of eight mice (Fig 4D) .
T-cell biodistribution in vivo
To study the biodistribution of T cells, radiolabeled T cells were injected intravenously into mice bearing two V K C K tumors: one in their right thigh and another in their left thigh. At 1 day before the intravenous injection of radiolabeled T cells, tumors on their right and left thighs of mice were injected with AdV-TNF-␣ and AdV-pLpA, respectively. At 2 and 24 hours after i.v. administration of radiolabeled T cells, we investigated the in vivo biodistribution of T cells by measuring the radioactivity present in dissected organs. Our data showed that the radiolabeled T cells almost immediately accumulated in capillary rich, well-perfused organs such as the lung, liver, spleen and kidneys, with values of 39.17, 9.80, 14.64, and 11.10 ϫ 10 5 cpm/g, respectively ( Table 6 ). The radioactivity detected in tumors was much lower compared with that in the above organs. Furthermore, there was no significant difference between tumors injected with AdV-TNF-␣ (1.64 ϫ 10 5 cpm/g) and those injected with AdV-pLpA (1.78 ϫ 10 5 cpm/g). As expected, the amount of radioactivity in the lungs rapidly decreased with time. At 24 hours, most of the detectable dose was in the spleen (20.03 ϫ 10 5 cpm/g), indicating that most of the injected radiolabeled T cells were trapped in the spleen. Interestingly, the radioactivity located in tumors injected with AdV-TNF-␣ (1.77 ϫ 10 5 cpm/g) was three times greater than that in tumors injected with AdV-pLpA (0.68 ϫ 10 5 cpm/g), indicating that T cells favored infiltration into tumors injected with AdV-TNF-␣ versus AdV-pLpA.
DISCUSSION
There is growing evidence that solid tumors possess characteristics that could effectively prevent their immune destruction. These include (a) the generation of tumor-induced suppressor T cells, 22 (b) the secretion of immunosuppressive factors such as transforming growth factor-␤ 23 and IL-10, 24 (c) the alteration in T-cell signal transduction in the tumor-bearing host, 25, 26 (d) the tumor induction of T-cell apoptosis by expression of Fas ligand, 27 (e) the development of peripheral tolerance to tumor Ags, 28, 29 and (f) the prevention of T-cell infiltration by tumor stroma. 30 Notably, most strategies for tumor immunotherapy in animals fail if initiated after the inoculated tumor cells have expanded beyond a critical mass and organized themselves into a vascularized solid tumor. This inability to kill established solid tumors may reflect a common situation in cancer patients, where antitumoral immune responses can frequently be detected but do not generally result in tumor rejection. 31 Thus, the solid tumor microenvironment may have unique characteristics, among which is an intrinsic resistance to the infiltration and function of tumor-specific lymphocytes.
In the present study, our data showed that V K C K -TNF-␣/B7-1 tumor cells expressing the B7-1 molecule and secreting TNF-␣ can induce tumor regression in syngeneic mice and protective immunity against V K C K tumors. The primary phase of the immunity is mediated by both CD4 ϩ and CD8 ϩ T cells, whereas the effector phase is mediated by only CD8 ϩ T cells. The phenotypes ‡The mean tumor weight in this group of mice is not significantly different (P Ͼ .1) from the control group (Student's t test).
§The mean tumor weight in this group of mice is significantly different (P Ͻ .01) from the control group and the group of mice treated with V K C K -TNF-␣/B7-1 vaccine (Student's t test).
¶The mean tumor weight in this group of mice is significantly different (p Ͻ .01) from the group of mice treated with AdV-TNF-␣ and the control group (nonparametric Mann-Whitney U test). of V K C K -and V K C K -TNF-␣/B7-1-reactive T cells were further characterized by using IFN-␥ and IL-4 ELISA kits. Our data showed that T cells from V K C K tumorbearing susceptible mice secreted high levels of the Th2 cytokine IL-4, whereas T cells from resistant mice inoculated with V K C K -TNF-␣/B7-1 cells secreted high levels of the Th1 cytokine IFN-␥. Therefore, we conclude that the regression of tumor cells engineered to secrete TNF and expressing B7-1 is related to a shift in the immune response of the host from Th2 to Th1. Our findings are in accord with other studies on animal models that reported that (a) the gradual loss of Th1 populations in the spleens of mice was observed during progressive tumor growth 32 and (b) the up-regulation of the Th1 cytokine response is associated with tumor regression, 33, 34 whereas that of Th2 cytokines leads to a fatal outcome. 35 Furthermore, a recent report on melanoma lesions suggested a significant correlation between type 1 cytokine elaboration and tumor regression. 36 Many previous studies have tried to treat established tumors in animal models with gene-modified vaccines using engineered tumor cells expressing B7-1 and/or secreting various cytokines. [37] [38] [39] [40] [41] [42] [43] [44] Although the results derived from these studies may not be comparable with each other because the growth rate of different tumor cell lines and the cell dosage for each vaccination varied, the general conclusion is that a far greater tumor burden can be rejected when non-tumor-bearing animals are immunized first, followed sometime later by the tumor challenge, compared with immunization after establishment of the tumor. It is also to be noted that because most of these studies dealt with small tumors that had been resident in the host mice for relatively short periods of time, no evidence was presented showing that the tumors were well-vascularized and hence truly established. Our data in the present study similarly showed that the vaccination with V K C K -TNF-␣/B7-1 cells was able to cure only 3-day V K C K tumors but not the 10-day established V K C K tumors. Only in a recent study did Fallarino et al 45 achieve success in treating well-established P815 tumors measuring Ն0.5 cm in diameter; this group used engineered P815 cells secreting IL-12, which favors a Th1 response.
In our previous studies as well as the present one, we showed that i.t. injection of AdV-TNF-␣ induced extensive tumor necrosis as early as the following day and also resulted in significant tumor inhibition, although it was unable to eradicate any well-established tumors. 18, 19 The antitumoral activity of TNF-␣ is mediated in at least three ways. The first mechanism is mediated by its direct cytotoxicity to tumor cells by inducing apoptosis through engagement of the p55 TNF-␣ receptor I. 46 The second mechanism is through its immune activation. TNF-␣ is an immune mediator capable of activating macrophages, natural killer cells, and T cells 47 by its binding to the p75 TNF-␣ receptor II. 46 The antitumoral immunity of TNF-␣ has been reported to be due to its activation of tumor-specific T cells. 3, [17] [18] [19] The third mechanism is mediated by its effects on tumor vasculature by deactivation of ␣ V ␤ 3 integrin on angiogenic endothelial cells, leading to a lack of adhesion and apoptosis, 48 promoting intravascular thrombosis, and inducing ischemic necrosis 49 and, consequently, tumor regression. 46 Considering the early onset of the necrosis, it is unlikely that this is due to the activation of T cells; rather, this necrosis is most likely the result of mediation through the third mechanism, in which the ischemic damage secondarily invokes an influx of polymorphonuclear and mononuclear cells. Various chemokines may be secreted by these inflammatory cells.
To combat the well-established tumors, we conducted combinational immunotherapy with a gene-modified vaccine and AdV-mediated TNF-␣ gene transfer in animal models. Our data showed that vaccination with V K C K -TNF-␣/B7-1 cells alone did not significantly inhibit the growth of 10-day tumors. An i.t. injection of AdV-TNF-␣ expressing TNF-␣ worked much better. It significantly inhibited the growth of established tumors by inducing extensive tumor necrosis, but could not completely abrogate these tumors. In contrast, combinational immunotherapy with V K C K -TNF-␣/B7-1 vaccine and AdV-mediated TNF-␣ gene transfer not only significantly inhibited tumor growth but also completely eradicated 10-day V K C K tumors in three of eight mice. This may be partly due to the fact that the infiltration of tumor-specific T cells into the V K C K tumors significantly increased with the injection of AdV-TNF-␣. The enhanced T-cell infiltration may be a chemotactic response induced by chemokines such as inflammatory protein-10 and macrophage inflammatory protein-1␤, which are secreted by neutrophils and mononuclear cells 50, 51 in tumor necrosis. 52, 53 In conclusion, the cotransfection of murine V K C K tumor with TNF-␣ and B7-1 resulted in reduced tumorigenicity and tumor regression. The inoculation of V K C K -TNF-␣/B7-1 cells induced further protective immunity against V K C K tumors; both CD4 ϩ and CD8 ϩ T cells were involved in the induction phase, whereas only CD8 ϩ T cells participated in the effector phase. Susceptible mice bearing V K C K tumors developed a Th2-dominant response, whereas resistant mice (i.e., with V K C K -TNF-␣/B7-1 tumor regression) developed a Th1-dominant response to V K C K , thus indicating that tumor regression is related to a shift in host cytokine profile from type 2 to type 1. Vaccination of V K C K -TNF-␣/B7-1 cells inhibited tumor formation after inoculation of 3 ϫ 10 6 V K C K cells and eradicated 3-day V K C K tumors but not the 7-or 10-day tumors. An i.t. injection of AdV-TNF-␣ by itself significantly inhibited tumor growth but did not eradicate any of the well-established tumors. However, combinational immunotherapy with vaccination of V K C K -TNF-␣/B7-1 cells and AdV-mediated TNF-␣ gene transfer completely abrogated well-established 10-day V K C K tumors in three of eight mice. We think that the present study will be useful not only in understanding the mechanisms responsible for efficient antitumoral immunity, but also in establishing a more effective immunotherapeutic approach for cancer patients.
